Novadaq Technologies (Novadaq Technologies) Forward PE Ratio : 0.00 (As of Apr. 26, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Novadaq Technologies Forward PE Ratio?

Novadaq Technologies's Forward PE Ratio for today is 0.00.

Novadaq Technologies's PE Ratio without NRI for today is 0.00.

Novadaq Technologies's PE Ratio for today is 0.00.

Novadaq Technologies Forward PE Ratio Historical Data

The historical data trend for Novadaq Technologies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novadaq Technologies Forward PE Ratio Chart

Novadaq Technologies Annual Data

Trend

2016-01

Forward PE Ratio

270.27

Novadaq Technologies Quarterly Data

Forward PE Ratio

Competitive Comparison of Novadaq Technologies's Forward PE Ratio

For the Diagnostics & Research subindustry, Novadaq Technologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novadaq Technologies's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Novadaq Technologies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Novadaq Technologies's Forward PE Ratio falls into.

Novadaq Technologies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Novadaq Technologies (NAS:NVDQ) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Novadaq Technologies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Novadaq Technologies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Novadaq Technologies (Novadaq Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Novadaq Technologies Inc (NAS:NVDQ) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.novadaq.com

Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.

Novadaq Technologies (Novadaq Technologies) Headlines

From GuruFocus

Baron Funds Comments on Novadaq Technologies

By Holly LaFon Holly LaFon • 01-20-2017

Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct

By Holly LaFon Holly LaFon • 02-14-2013